BIOLOGIC MEDICATIONS FOR SEVERE ASTHMA ARE EFFECTIVE IN THE REAL-WORLD, INCLUDING IN SUBGROUPS NOT STUDIED IN RANDOMIZED TRIALS

TOPIC: Allergy and Airway TYPE: Original Investigations PURPOSE: Several biologic therapies are now available for severe asthma (SA) treatment. The real-world effectiveness of is great interest has not been well-described in patient subgroups included randomized trials, such as patients with pre-bronchodilator FEV1 ≥ 80%, comorbid COPD, or significant smoking history. METHODS: CHRONICLE study an ongoing, observational US adults SA treated by allergists/immunologists pulmonologists. Eligible receiving biologics and/or maintenance systemic corticosteroids, plus those uncontrolled on high-dosage inhaled corticosteroids additional controllers. For enrolled patients, sites report exacerbations medications 12 months before enrollment every 6 after enrollment. starting a switching between 2 biologics, exacerbation rates were calculated the start/switch. To be included, required to have data full Results summarized overall specific interest. RESULTS: Between 2/27/2018 11/1/2020, 122 2559 patients; 409 151 newly started switched therapy, respectively, had incidence Overall, experienced 56% reduction exacerbations, from 1.75 0.77 per patient-year; anti-IgE therapy 44% (1.52 0.85), whereas anti–IL-5/IL-5R/IL-4R 60% (1.85 0.74). Across all reductions 52% (1.79 0.86) versus (vs) 63% (2.40 vs 0.89) highest pre-biologic BEC < 300 cells/mcL. other interest, rate 55% (1.74 0.78) 62% (2.04 without (1.91 1.07) 57% (1.73 0.74) reported COPD diagnosis, 45% (1.99 1.09) (1.61 0.59) current/former (Y/N). Patients 43% (1.54 0.88); 53% (1.38 0.65), another 40% (1.71 1.03). CONCLUSIONS: These results support asthma, validating extending findings randomized, placebo-controlled trials. CLINICAL IMPLICATIONS: Real-world use consistently associated including multiple prior DISCLOSURES: Employee relationship AstraZeneca Please note: >$100000 Added 04/21/2021 Christopher Ambrose, source=Web Response, value=Salary No relevant relationships Donna Carstens, Response Speaker/Speaker's Bureau $5001 - $20000 Bradley Chipps, value=Honoraria Boeringer Ingelheim Genentech Consultant GlaxoSmithKline value=Consulting fee Novartis Regeneron Sanofi Genzyme Shareholder LP since 2014 Eduardo Genofre, Removed Since value=Shareholder value=LTIs Advisory Committee Member AstraZeneca, Genentech, GSK, Novartis, Regeneron, Sanofi, Teva >24 04/20/2021 Njira Lugogo, GSK TEVA Funds devleoping CME presentations AKH 04/19/2021 value=Grant/Research Support Clinical trials institution funding developing Greentech trial 04/26/2021 AKH, Medscape NACE years 04/23/2021 Wendy Moore, 24 Reynold Panettieri, RIFM Equillium Genetech Sanofi/Regeneron Bayer Theravance Contracted Research Optikira Medimmune Maven Evelobio Johnson & AstraZeneca; RIFM; Equillium; Genentech; Thervance 04/22/2021 Sanofi/Regeneron; grant recipient Novartis; Optikira; Medimmune; Maven; Johnson; $1001 $5000 Principal Investigator $20001 $100000 MedImmune Reseaerch Institute Fragrance Materials Avillion OncoArendi Metera Julie Severance, PackHealth Weily Soong, $1-$1000 Grant: 8/2020 present